JP2024521209A - ｓｉＲＮＡ送達ベクター - Google Patents

ｓｉＲＮＡ送達ベクター Download PDF

Info

Publication number
JP2024521209A
JP2024521209A JP2023574125A JP2023574125A JP2024521209A JP 2024521209 A JP2024521209 A JP 2024521209A JP 2023574125 A JP2023574125 A JP 2023574125A JP 2023574125 A JP2023574125 A JP 2023574125A JP 2024521209 A JP2024521209 A JP 2024521209A
Authority
JP
Japan
Prior art keywords
negatively charged
formula
compound
substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574125A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521209A5 (https=
Inventor
コタムラジュ，スリジリダー
バトゥーラ，サレンダー・レッディ
シャイカ，アルタブ
ニーリ，パラヴィーン・クマール
サラヴヤ，パナンギパリ
バネルジー，ラジクマール
テナティ，ラジャマナール
ガジャラクシュミ，シングル
Original Assignee
カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ filed Critical カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ
Publication of JP2024521209A publication Critical patent/JP2024521209A/ja
Publication of JP2024521209A5 publication Critical patent/JP2024521209A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicinal Preparation (AREA)
JP2023574125A 2021-06-04 2022-06-03 ｓｉＲＮＡ送達ベクター Pending JP2024521209A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202111024926 2021-06-04
IN202111024926 2021-06-04
PCT/IB2022/055214 WO2022254405A1 (en) 2021-06-04 2022-06-03 siRNA DELIVERY VECTOR

Publications (2)

Publication Number Publication Date
JP2024521209A true JP2024521209A (ja) 2024-05-28
JP2024521209A5 JP2024521209A5 (https=) 2025-06-11

Family

ID=82558096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574125A Pending JP2024521209A (ja) 2021-06-04 2022-06-03 ｓｉＲＮＡ送達ベクター

Country Status (8)

Country Link
US (1) US20240277851A1 (https=)
EP (1) EP4346902A1 (https=)
JP (1) JP2024521209A (https=)
CN (1) CN117396227A (https=)
AU (1) AU2022287326A1 (https=)
BR (1) BR112023025242A2 (https=)
CA (1) CA3220535A1 (https=)
WO (1) WO2022254405A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用
CN120617243A (zh) * 2024-11-15 2025-09-12 江苏省肿瘤医院 瑞香素作为抑制剂在制备治疗三阴性乳腺癌的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2540234B (en) * 2015-02-19 2020-12-02 Council Scient Ind Res An antioxidant compound having anti atherosclerotic effect and preparation thereof
US11213960B2 (en) 2018-09-17 2022-01-04 John AMBIELLI Multi-tool and storage device
AR127082A1 (es) * 2019-11-22 2023-12-20 Council Scient Ind Res Compuestos antiinflamatorios para el tratamiento de trastornos cutáneos

Also Published As

Publication number Publication date
CA3220535A1 (en) 2022-12-08
US20240277851A1 (en) 2024-08-22
WO2022254405A1 (en) 2022-12-08
AU2022287326A1 (en) 2023-11-30
EP4346902A1 (en) 2024-04-10
CN117396227A (zh) 2024-01-12
BR112023025242A2 (pt) 2024-02-20

Similar Documents

Publication Publication Date Title
Hamimed et al. Nanotechnology in drug and gene delivery
KR20230144574A (ko) 폴리옥사졸린-지질 접합체, 및 이를 포함하는 지질 나노입자 및 제약 조성물
Li et al. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia
Li et al. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy
Yang et al. Structure-directing star-shaped block copolymers: supramolecular vesicles for the delivery of anticancer drugs
CN104936622A (zh) 包封在颗粒中的靶向缀合物及其制剂
EP2515946A2 (en) Nanoconjugates and nanoconjugate formulations
JP2011105792A (ja) ブロックコポリマー、ブロックコポリマー−金属錯体複合体、及びそれを用いた中空構造体キャリア
JP2023538640A (ja) 脂質ナノ粒子
CA3062624C (en) Quinic acid-modified nanoparticles and uses thereof
JP2024521209A (ja) ｓｉＲＮＡ送達ベクター
Markowicz-Piasecka et al. Dendrimers in drug delivery
KR102465349B1 (ko) 신규 이온화 지질 및 이를 포함하는 지질 나노입자
Gu et al. Self-assembly dual-responsive NO donor nanoparticles for effective cancer therapy
Lages et al. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects
Tran et al. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages
CN113710323B (zh) 偶联物及癌治疗剂
JP7179154B2 (ja) ウイルス送達用ポリマーナノ粒子組成物及びその製造方法
WO2012017551A1 (ja) 疾患治療薬
Yuan et al. In vivo metabolizable branched poly (ester amide) based on inositol and amino acids as a drug nanocarrier for cancer therapy
CN120359207A (zh) 一种阳离子脂质材料的制备及应用
KR102172987B1 (ko) 엽산 수용체 표적능 및 엔도솜막 분해능을 갖는 엽산-폴리(입실론-카프로락톤)-엽산 고분자 및 이의 용도
CN114746124A (zh) 包含活性剂沉淀物的递送系统复合物和使用方法
CN120483890B (zh) 多叔胺多尾链可电离阳离子脂质、包含其的组合物及用途
US20240245617A1 (en) Lipid-based topical injection formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260423